Ibrutinib produces high response rates in ABC-DLBCL; these patients benefit from ibrutinib therapy owing to the selectively acquired mutations that foster chronic active BCR signaling in ABC-DLBCL. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.